Jack F Rogers

US Patent:

6849405, Feb 1, 2005

Filed:

Jul 24, 2001

Appl. No.:

09/910757

Inventors:

Jack Rogers - Jamaica Plain MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C12Q 168
G01N 3567
C07H 1204

US Classification:

435 6, 436504, 536 231, 536 241

Abstract:

The present invention is directed to a DNA element that enhances the translation of the human amyloid precursor protein (APP) gene. The enhancer may be incorporated into expression vectors to enhance recombinant protein production. In addition, the invention is directed to an assay that utilizes vectors containing the translation enhancer element for the purpose of identifying agents that modulate the expression of the human amyloid precursor protein. These agents will ultimately be used to suppress APP expression in patients with Alzheimer's disease.

US Patent:

7034000, Apr 25, 2006

Filed:

Oct 17, 2001

Appl. No.:

09/978178

Inventors:

Jack Rogers - Arlington MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

A61K 38/17
C07K 14/435

US Classification:

514 13, 530326

Abstract:

The present invention is directed to certain peptides that correspond to sequence elements within the human Alzheimer's amyloid precursor protein (APP). These peptides may be used to protect cells from iron catalyzed oxidative damage.

US Patent:

20080003570, Jan 3, 2008

Filed:

Dec 22, 2005

Appl. No.:

11/316339

Inventors:

Jack Rogers - Arlington MA, US
Avi Friedlich - Brockton MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C12Q 1/68
C07H 21/00
C07K 2/00
C12N 1/00
C12N 15/63
C12N 5/10
C12P 21/02

US Classification:

435006000, 435243000, 435320100, 435325000, 435069100, 530300000, 536023100

Abstract:

The invention relates to translation enhancer elements that enhance translation of the gene encoding the human microtubule-associated tau protein and nucleic acid molecules that enhance translation of the gene encoding the human α-synuclein protein. The translation enhancer elements of the invention are useful in compositions and methods for identifying compounds for the prevention and/or treatment of neurodegenerative disease. The invention also includes in some aspects, vectors that include a translation enhancer element of the invention. The invention also includes the use of enhancer element containing vectors in methods to produce recombinant protein and in assays to identify compounds that modulate expression of tau protein or α-synuclein protein.

US Patent:

20100151520, Jun 17, 2010

Filed:

Dec 15, 2009

Appl. No.:

12/638494

Inventors:

Jack Rogers - Arlington MA, US
Avi Friedlich - Charlestown MA, US

International Classification:

C12P 21/02
C07H 21/00
C12N 15/74
C12N 5/10

US Classification:

435 691, 536 231, 4353201, 435325

Abstract:

The invention relates to translation enhancer elements that enhance translation of the gene encoding the human microtubule-associated tau protein and nucleic acid molecules that enhance translation of the gene encoding the human α-synuclein protein. The translation enhancer elements of the invention are useful in compositions and methods for identifying compounds for the prevention and/or treatment of neurodegenerative disease. The invention also includes in some aspects, vectors that include a translation enhancer element of the invention. The invention also includes the use of enhancer element containing vectors in methods to produce recombinant protein and in assays to identify compounds that modulate expression of tau protein or α-synuclein protein.

US Patent:

63101971, Oct 30, 2001

Filed:

Nov 9, 1998

Appl. No.:

9/188118

Inventors:

Jack Rogers - Jamaica Plain MA

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C07H 2104
C12N 1509
C12N 510
C12N 1503

US Classification:

536 241

Abstract:

The present invention is directed to a DNA element that enhances the translation of the human amyloid precursor protein (APP) gene. The enhancer may be incorporated into expression vectors to enhance recombinant protein production. In addition, the invention is directed to an assay that utilizes vectors containing the translation enhancer element for the purpose of identifying agents that modulate the expression of the human amyloid precursor protein. These agents will ultimately be used to suppress APP expression in patients with Alzheimer's disease.